Payment overview · 2025
General Payments
$1,132.95
42 reported records · 8 companies
Healthcare provider profile · identity verified
Nelson James Owyoung, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ALHAMBRA, CA · NPI 1073543641
Verified facts
What the public records show
CMS Open Payments records show Nelson James Owyoung, M.D. received $1,132.95 in general payments during 2025 across 42 reported records.
SK Life Science, Inc. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gocovri, Xcopri.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Apokyn as an associated drug or biological on 1207 records involving 338 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Apokyn by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Gocovri by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$459.50 | 40.6% | 21 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $157.92 | 13.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.02 | 12.5% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $134.87 | 11.9% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.83 | 10.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.90 | 6.7% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$25.75 | 2.3% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $15.16 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,057.05 | 40 |
| Education | $75.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $142.02 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $134.87 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $132.99 | 7 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $123.08 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $75.90 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $23.32 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gocovri gocovri |
2025 | Gocovri | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Apokyn open payments reported associated product |
CMS Open Payments — General Payments 1207 supporting records · 338 recipient NPIs · example record 1241843684 |
Apokyn · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 271 | 49 |
| Memantine Hcl | Memantine Hcl | 129 | 23 |
| Donepezil Hcl | Donepezil Hcl | 122 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 23 |
| Lacosamide | Lacosamide | 91 | 11 |
| Rytary | Carbidopa/Levodopa | 79 | 15 |
| Gocovri | Amantadine Hcl | 76 | suppressed |
| Carbamazepine | Carbamazepine | 74 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 72 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Sertraline Hcl | Sertraline Hcl | 63 | 18 |
| Briviact | Brivaracetam | 62 | suppressed |
| Gabapentin | Gabapentin | 56 | 15 |
| Xcopri | Cenobamate | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 15 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 48 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Famotidine | Famotidine | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 44 | suppressed |
| Eliquis | Apixaban | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Vimpat | Lacosamide | 41 | suppressed |
| Furosemide | Furosemide | 39 | suppressed |
| Metformin Hcl | Metformin Hcl | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Losartan Potassium | Losartan Potassium | 31 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Carbidopa | Carbidopa | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | 12 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Lamictal | Lamotrigine | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Onfi | Clobazam | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | 11 |
| Clobazam | Clobazam | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Apokyn | Apomorphine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Droxidopa | Droxidopa | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ongentys | Opicapone | 14 | suppressed |
| Zolmitriptan | Zolmitriptan | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbatrol | Carbamazepine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,132.95 · 42 records | SK Life Science, Inc. | AUSTEDO XR, Gocovri, NURTEC ODT, Nayzilam, ULTOMIRIS, UPLIZNA, VALTOCO, XCOPRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gocovri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with MDD US Operations, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error